𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P011 GLOBAL SAFETY OF ADALIMUMAB IN CROHN'S DISEASE CLINICAL TRIALS

✍ Scribed by J.F. Colombel; R. Panaccione; W.J. Sandborn; P. Rutgeerts; S.B. Hanauer; W. Reinisch; P.F. Pollack; J.D. Kent; A.T. Cardoso; W. Lau


Book ID
119637209
Publisher
Oxford University Press
Year
2008
Weight
70 KB
Volume
2
Category
Article
ISSN
1873-9954

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Adalimumab safety in global clinical tri
✍ Jean-FrΓ©dΓ©ric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr